Adverse events and tolerability of combined durvalumab and tremelimumab versus durvalumab alone in solid cancers: a systematic review and meta-analysis
Background: Recently, the combination of durvalumab and tremelimumab, two immune checkpoint inhibitors, for the treatment of different types of cancers has been considered; however, its overall effects, including its safety, are still unclear and need to be further investigated. Objectives: The aim...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
Multidisciplinary Digital Publishing Institute
2022
|